CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pear Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pear Therapeutics Inc
200 State Street
Phone: (646) 932-2774p:646 932-2774 BOSTON, MA  02109  United States Fax: (302) 636-5454f:302 636-5454
This company's Plan of Liquidation went into effect on 5/23/2024
This entity represents the bankrupt estate of the former business (assets) of Pear Therapeutics Inc that was not sold to Click Therapeutics, Harvest BIO, Nox Health Group and Welt pursuant to section 363 of the US bankruptcy code in May of 2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022YesYesYes-Yes

Industries
SIC Code Description
7371 Computer programming services
8731 Commercial physical and biological research
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Principal Executive Officer, Chief Financial Officer, Chief Operating Officer, Treasurer, Assistant Christopher D.Guiffre 53 4/6/2023 12/1/2021
Chief People Officer KatherineJeffery 54 12/1/2021 12/1/2021
Chief Compliance Officer, General Counsel, Secretary RonanO'Brien 12/1/2021 12/1/2021
8 additional Officers and Directors records available in full report.

Business Names
Business Name
PEAR
Pear Therapeutics Inc
Pear Therapeutics Inc
PEARQ
THMA
THMAU

General Information
Outstanding Shares: 142,739,169 (As of 3/30/2023)
Shareholders: 168
Stock Exchange: OTC
Federal Tax Id: 854103092
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 2, 2024